Key result
Bariatric surgery induced a mean weight loss of 31.3 kg over 12 months and significantly improved hormonal and inflammatory profiles, particularly in patients who achieved type 2 diabetes remission.
Why the study?
Bariatric surgery mitigates obesity-related type 2 diabetes, but few studies have elucidated the mechanisms underlying post-surgical diabetes remission.
Does bariatric surgery improve hormonal and inflammatory biomarker profiles in Korean patients with morbid obesity?
Cohort (n=63)
Yes
Does bariatric surgery improve hormonal and inflammatory biomarker profiles in Korean patients with morbid obesity?
Mean Difference: -31.3
Absolute Event Rate: 77.5% vs 108.8%
p-value: p=<0.0001
Bariatric surgery improves metabolic and inflammatory profiles in morbidly obese Korean patients, with specific hormonal and cytokine reductions distinguishing those who achieve type 2 diabetes remission.
Bariatric surgery-linked biomarker shifts may aid remission prediction in obese patients; leaves open causal roles and generalizability beyond this cohort.
Background: Bariatric surgery (BS) has a superior effect on reducing body weight and fat in patients with morbid obesity. As a result, BS mitigates obesity-related complications such as type 2 diabetes (T2D). However, few studies have shown the mechanism underlying diabetes remission after surgery. This study aimed to investigate the differences in serum hormone and inflammatory cytokine levels related to diabetes before surgery and during 12 months of follow-up in Korean patients with obesity. Methods: The study participants were patients with morbid obesity (n=63) who underwent sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) between 2016 - 2017 at seven tertiary hospitals in Korea. The patients were followed for 1 year after surgery. Results: Sixty-three patients had significant weight loss after surgery and showed improvements in clinical parameters and hormonal and inflammatory profiles. Among them, 23 patients who were diabetic preoperatively showed different remission after surgery. The levels of inflammation-related clinical parameters changed significantly in the remission group, and serum inflammatory cytokine and hormones significantly decreased at certain points and showed an overall decreasing trend. Conclusions: Our study found postoperative changes of factors in blood samples, and the changes in hormones secreted from the three major metabolic tissue (pancreas, adipose, and gut) along with the differences in multi-origin inflammatory cytokines between remission and non-remission groups provide a path for understanding how the effect of BS in improving glucose metabolism is mediated.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) conducted a cohort in Morbid obesity (n=63). Bariatric surgery (Sleeve gastrectomy or Roux-en-Y gastric bypass) vs. Baseline (pre-surgery) was evaluated on Change in body weight at 12 months (mean weight loss of 31.3 kg, p=<0.0001). Bariatric surgery induced a mean weight loss of 31.3 kg over 12 months and significantly improved hormonal and inflammatory profiles, particularly in patients who achieved type 2 diabetes remission.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: